Navigation Links
Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
Date:9/2/2008

ls of this study tomorrow, Wednesday, September 3, 2008 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). Participants can access the live conference call by dialing 1-800-894-5910 (US) or 785-424-1052 (International) using the conference ID: 7GNRH. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com.

If you are unable to attend the Webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600. A replay of the Conference Call will be available approximately one hour after the conclusion of the call by dialing 1-800-374-0934 (US) or 402-220-0680 (International) using the conference ID: 7GNRH. The call will be archived for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome (IBS), anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with the Company's GnRH program and Company overall. Specifically, the risks and uncertainties the Company faces with respect to the Com
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Neurocrine Biosciences Reports First Quarter 2008 Results
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
10. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
11. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , February 26, 2015 ... Outlook 2015: First -In- Class Innovations and Cost ... for Large Cap Pharmaceutical Companies research report to ... According to this Global Pharma US & ... as productivity measurements, divestment of non-core assets result ...
(Date:2/26/2015)... , Feb. 26, 2015  Spring Bank ... therapeutics for the treatment of Hepatitis B virus ... closing of a $22 million financing. Funds from ... 9200, a novel, broad spectrum antiviral agent derived ... acid hybrid (SMNH) chemistry platform, into Phase II ...
(Date:2/26/2015)... 26, 2015 Integrity Applications, Inc. (OTCQB: IGAP) ... model DF-F, a noninvasive  device that tracks blood glucose ... Ph.D., will head its new scientific advisory board that ... field of Diabetes research, monitoring and treatment. ... Chief Executive Officer and Head, Business Development of Profil ...
Breaking Medicine Technology:Global Pharma U.S. and EU Outlook 2015 Market Research Report 2Global Pharma U.S. and EU Outlook 2015 Market Research Report 3Global Pharma U.S. and EU Outlook 2015 Market Research Report 4Spring Bank Pharmaceuticals Completes $22 Million Financing 2Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 2Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 3Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 4
... , , ... Remedies announced today that its NutraRx brand of natural ... country to receive the Emerson EQP Seal in recognition of the ... "After a rigorous evaluation by Emerson Ecologics of our NutraRx brand ...
... ALBUQUERQUE, N.M. , Feb. 16 ... develops and markets proprietary genomic tests, today announced an ... promote its diagnostic services to gastroenterologists throughout the ... gastroenterology-focused sales force will introduce Exagen,s proprietary gene expression ...
Cached Medicine Technology:Native Remedies' NutraRx Brand of Natural Products for Medical Practitioners Among First to Earn Prestigious 'Emerson EQP Seal' 2Native Remedies' NutraRx Brand of Natural Products for Medical Practitioners Among First to Earn Prestigious 'Emerson EQP Seal' 3Exagen Diagnostics Enters Into Exclusive Agreement With EndoChoice 2
(Date:2/27/2015)... February 27, 2015 With Spring’s wet weather ... the condition of their crawl spaces in mind. The ... the most common FAQs regarding crawl space conditions and repairs. ... answer to owners that are confused as to how water ... “One of the most common ways is through cracks in ...
(Date:2/27/2015)... 2015 Is it reasonable – and appropriate ... and games, and possible to do so without causing impossible ... might be at high risk for concern and could also ... issues being addressed by two introductory bills, Int. 85 ... last month in New York City. More specifically, these ...
(Date:2/27/2015)... 27, 2015 Prescription Drug “Take-Back” ... Drug Enforcement Agency (DEA). Today, local ... to utilize the “Take-Back” guidelines for the proper ... , Eufaula Prescription Drug Disposal Event , The ... in Eufaula, Oklahoma as the “Take-Back” site for ...
(Date:2/27/2015)... Miami, FL (PRWEB) February 27, 2015 If ... it’s the mere suggestion of a head lice outbreak at ... getting rid of this persistent parasite is nothing short of ... passed back and forth among their children, or within their ... control, one of the kids starts scratching again. , Local ...
(Date:2/27/2015)... to a Feb. 12, 2015 news release by Verastem, ... by killing cancer stem cells, has received orphan drug designation ... in the treatment of mesothelioma.* According to the release, orphan ... development of drugs for the treatment of rare diseases. ... Melinda Helbock, Founder of The Law Office of Melinda J. ...
Breaking Medicine News(10 mins):Health News:Crawl Space FAQs are Answered in Clean Crawls Latest Article 2Health News:NYSATA Athletic Trainers Provide Expert Testimony at NYC Youth Concussion and Sports Safety Hearing 2Health News:NYSATA Athletic Trainers Provide Expert Testimony at NYC Youth Concussion and Sports Safety Hearing 3Health News:Narconon Arrowhead Promotes Local Prescription Drug Take Back Day 2Health News:Narconon Arrowhead Promotes Local Prescription Drug Take Back Day 3Health News:Anxiety over head lice among Miami parents as surge in head lice cases reported by local lice removal company Lice Troopers 2Health News:New Drug Receives FDA Approval as Orphan Drug for the Treatment of Mesothelioma 2Health News:New Drug Receives FDA Approval as Orphan Drug for the Treatment of Mesothelioma 3
... of time or drink continuously over a number of days ... says a study.// ,Sharon Wilsnack, from the University ... other researchers studied the alcohol intake of 6,009 men and ... online edition of BBC News. , ,The research, carried ...
... Persons treated with Interferon (IFN)to treat chronic hepatitis C ... phase itself//. Retinopathy can develop within two weeks from commencement ... in the journal Investigative Ophthalmology & Visual Science (IOVS)in the ... in Japan gauged the changes in diameter of ...
... final awakening' - Walter Scott// ... president of Iraq, Saddam Hussein, was sent to the gallows for ... that he slaughtered 148 fellow countrymen, who were Shias, and other ... use in all societies to wipe out political dissent. In recent ...
... Lupin Ltd has received tentative approval from the US ... Sertraline Hydrochloride for// treatment of major depressive disorder. ... AB-rated generic equivalent of Pfizer's Zoloft tablets of 25mg, ... intends to launch the generic (drug) on final approval, ...
... over the last four months of 2006, when compared with ... Health Agency on Dec 16. ,Flu season normally ... the Calgary Health Region monitors likely outbreaks during this time. ... fever, dry coughs and aching muscles. ,“One thing ...
... drug pexelizumab immediately before and for 24 hours after ... did not have any significant// treatment effect compared to ... JAMA. The medication had shown promise in preliminary studies. ... on an electrocardiogram following a heart attack) is a ...
Cached Medicine News:Health News:'Hooded Horror': Death by Hanging 2Health News:'Hooded Horror': Death by Hanging 3Health News:Drug Therapy Offers Little Benefit for Some Patients Undergoing Angioplasty or Stent Procedure 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: